ACB Stock Analysis: Buy, Sell, or Hold?
ACB - Aurora Cannabis Inc. Common Shares
$3.92
0.02 (0.51%)
â˛
5d:
-4.39%
30d:
-2.73%
90d:
+44.65%
WAIT
LOW Confidence
Analysis Updated: Oct 2, 2026 12:00 AM ET
Earnings: Nov 04, 2026
30d
Get Alerted When ACB Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: ACB is fairly priced but lacks strong directional signals. At 0% expected growth, valuation appears cheap. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: ACB is fairly priced but lacks strong directional signals. At 0% expected growth, valuation appears cheap. Wait for clearer setup or better entry on dips.
In-depth Analysis How we analyze
Valuation Analysis: ACB is currently trading at $3.92, which is considered fair relative to its 30-day fair value range of $3.84 to $4.09. From a valuation perspective, the stock is trading at a discount (Forward PE: -653.3) compared to its historical average (43.0). At these levels, the market is pricing in 0% annual earnings growth.
Technical Outlook: Technically, ACB is in a uptrend. The price is currently testing key support at $3.81. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock scores a mixed 40/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $6.23 (+58.8%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, ACB is in a uptrend. The price is currently testing key support at $3.81. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock scores a mixed 40/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $6.23 (+58.8%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$3.84 -
$4.09
Company Quality Score
41/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
72.4%
Protect Your Profits
Holding ACB? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- NEUTRAL: Price in fair range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 58.8% below Wall St target ($6.23)
- WARNING: Composite score 41/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$3.84 -
$4.09
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$3.82
Resistance Level
$4.30
Current Trend
Uptrend
Technical data as of
Oct 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-653.33
Wall Street Target
$6.23
(+58.8%)
Revenue Growth (YoY)
-8.8%
Earnings Growth (YoY)
-94.7%
Profit Margin
-38.2%
PE vs Historical
-653.3 vs 43.0
CHEAP
Share & Embed Analysis
Last updated: October 04, 2026 1:18 PM ET
Data refreshes hourly during market hours. Next update: 2:18 PM
Data refreshes hourly during market hours. Next update: 2:18 PM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ACB showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences IâĻ |
STRONG BUY
28 analysts |
$208 | 62 BUY |
|
ALKS
Alkermes Plc |
STRONG BUY
19 analysts |
$57 | 62 BUY |
|
ELAN
Elanco Animal Health |
STRONG BUY
16 analysts |
$31 | 59 HOLD |
|
AQST
Aquestive Therapeutics IâĻ |
STRONG BUY
9 analysts |
$9 | 67 BUY |
|
AMLX
Amylyx Pharmaceuticals IâĻ |
STRONG BUY
12 analysts |
$42 | 54 HOLD |
Advanced ACB Option Strategies
Professional options setups generated by AI based on today's ACB price and gamma walls.
